Barium Sulfate
drugOn this page
Also known as Barii sulfasBarite (ba(so4))Barium sulfate component of readi-cat 2BarytesC.i. pigment white 21C.i. pigment white 22Ci 77120E-z-cat dryE-z-hdE-z-paqueEntero vu 24%Liquid e-z-paqueReadi-cat 2Readi-cat 2 smoothieReadi-cat 2 smoothiesReadi-cat2Readi-cat2 smoothiesSachtoperse ab-tm 18383Spezialsorte ai
Summary
Barium Sulfate (CHEMBL2105897) is an approved small-molecule radioopaque medium.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Clinical trials: 2
- Chemistry: 233.39 Da · BaO4S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2105897 |
| Name | Barium Sulfate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 24414 |
| ChEBI | CHEBI:133326 |
| Molecular formula | BaO4S |
| Molecular weight | 233.39 |
| InChIKey | TZCXTZWJZNENPQ-UHFFFAOYSA-L |
SMILES: [O-]S(=O)(=O)[O-].[Ba+2]
IUPAC name: barium(2+) sulfate
ChEBI definition: A metal sulfate with formula BaO4S. Virtually insoluble in water at room temperature, it is mostly used as a component in oil well drilling fluid it occurs naturally as the mineral barite.
Pharmacological roles (ChEBI): radioopaque medium.
Also known as: Barii sulfas, Barite (ba(so4)), Barium sulfate, Barium sulfate component of readi-cat 2, Barytes, C.i. pigment white 21, C.i. pigment white 22, Ci 77120, E-z-cat dry, E-z-hd, E-z-paque, Entero vu 24%
Patent coverage: 129,961 distinct patent families (326,705 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00212433 | PHASE4 | COMPLETED | Optimisation and Performance of Reduced Preparation CT Colography |
| NCT02946203 | PHASE4 | COMPLETED | Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.